Floatz logo

AZD9291

Brain Metastases

Shandong Cancer Hospital and InstituteSmall moleculePhase 3Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
73/ 100

Competitive context

64 Active assets in the Brain Metastases cohort.

Asset / SponsorPhaseRating
TRASTUZUMAB
Iambic Therapeutics, Inc
Phase 4BB
Icotinib
Betta Pharmaceuticals Co., Ltd.
Phase 3BB
Trastuzumab Deruxtecan
Baptist Health South Florida
Phase 4BB
Capecitabine
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3BB
Panobinostat
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 3BB

View all 50 →

Same molecule, other indications

AZD9291 is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
EGFR-TKI Resistant MutationDormant
B
Indicative ·
60 / 100
View asset →
AZD9291Dormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →